Pharmagreen Biotech (Pharmagreen Biotech) Debt-to-EBITDA : -0.70 (As of Jun. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Pharmagreen Biotech Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pharmagreen Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.28 Mil. Pharmagreen Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.12 Mil. Pharmagreen Biotech's annualized EBITDA for the quarter that ended in Jun. 2023 was $-0.57 Mil. Pharmagreen Biotech's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -0.70.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Pharmagreen Biotech's Debt-to-EBITDA or its related term are showing as below:

PHBI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.99 Med: -0.1 Max: 0
Current: -0.99

PHBI's Debt-to-EBITDA is ranked worse than
100% of 659 companies
in the Drug Manufacturers industry
Industry Median: 1.71 vs PHBI: -0.99

Pharmagreen Biotech Debt-to-EBITDA Historical Data

The historical data trend for Pharmagreen Biotech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmagreen Biotech Debt-to-EBITDA Chart

Pharmagreen Biotech Annual Data

Trend

Apr08

Apr09

Sep18

Sep19

Sep20

Sep21

Sep22

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.10

-0.39

-0.07

-0.41

Pharmagreen Biotech Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-EBITDA	Get a 7-Day Free Trial															0.36	-0.81	-4.95	-0.72	-0.70

Competitive Comparison of Pharmagreen Biotech's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmagreen Biotech's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pharmagreen Biotech's Debt-to-EBITDA falls into.

Pharmagreen Biotech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pharmagreen Biotech's Debt-to-EBITDA for the fiscal year that ended in Sep. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.219	+	0.119)	/	-0.828
	=	-0.41

Pharmagreen Biotech's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.28	+	0.12)	/	-0.572
	=	-0.70

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2023) EBITDA data.

Pharmagreen Biotech (OTCPK:PHBI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Pharmagreen Biotech Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pharmagreen Biotech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmagreen Biotech (Pharmagreen Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmagreen Biotech Inc (OTCPK:PHBI) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

112 North Curry Street, Carson, NV, USA, 89703

Website

https://www.pharmagreen.ca

Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.